More than 1,000 genes may serve as possible treatment targets for individuals with kidney disease, according to a new study, ...

Nearly all children with ANCA-associated vasculitis demonstrate active kidney disease at diagnosis, and their renal function ...

New research at the University of Alberta may make it easier to diagnose serious diseases that disrupt the body's energy ...

Vertex reported solid fourth-quarter numbers throughout its business. While the company's earnings per share came in slightly ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle; Chief Operating Officer, Executive Vice President; Vertex Pharmaceuticals Inc Charles ...

The study reveals new evidence that reinforces the health consequences of exposure. Researchers identify troubling cause of certain kidney damage: 'We can't actually provide recommendations to help' ...

With 103 lung transplants and one heart-lung transplant in 2024, MHH is the leader in the Eurotransplant network. The lung transplant team relies on minimally invasive procedures and innovative ...

Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $3.98 per share for the fourth quarter of 2024, ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in ...